Wow_老虎社区_美港股上老虎

david1
2021-05-12

Wow

Samsung BioLogics denies report on Pfizer vaccine production

on Wednesday said a report it was in talks with Pfizer Inc to begin production of the U.S. drugmaker

Samsung BioLogics denies report on Pfizer vaccine production

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":193812132,"tweetId":"193812132","gmtCreate":1620779291326,"gmtModify":1631887181588,"author":{"id":3581583021301915,"idStr":"3581583021301915","authorId":3581583021301915,"authorIdStr":"3581583021301915","name":"david1","avatar":"https://static.tigerbbs.com/e77918479b6e06c841251d51591c6148","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wow</p></body></html>","htmlText":"<html><head></head><body><p>Wow</p></body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/193812132","repostId":2134269356,"repostType":4,"repost":{"id":"2134269356","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1620777935,"share":"https://www.laohu8.com/m/news/2134269356?lang=&edition=full","pubTime":"2021-05-12 08:05","market":"us","language":"en","title":"Samsung BioLogics denies report on Pfizer vaccine production","url":"https://stock-news.laohu8.com/highlight/detail?id=2134269356","media":"Reuters","summary":"on Wednesday said a report it was in talks with Pfizer Inc to begin production of the U.S. drugmaker","content":"<p>on Wednesday said a report it was in talks with Pfizer Inc to begin production of the U.S. drugmaker's COVID-19 vaccine in South Korea as early as in August was \"not factual.\"</p>\n<p>The Korea Economic Daily reported earlier that the biotech arm of Samsung Group had been revamping production lines at its plant in Songdo to produce the Pfizer vaccine, which was jointly developed by BioNTech . The plant had the capacity to make up to 1 billion doses per year, the report said, quoting an unnamed high-level government official.</p>\n<p>Samsung BioLogics said in a <a href=\"https://laohu8.com/S/AONE\">one</a>-line filing to the stock exchange that the report was \"not factual\". The company did not respond to requests for more detail.</p>\n<p>Pfizer and the Korea Disease Control and Prevention Agency (KDCA) in charge of COVID-19 vaccine procurement were not immediately available for comment.</p>\n<p>South Korea has a contract with Pfizer to purchase 66 million doses of its COVID-19 vaccine. The country also has contracts to acquire a total of 192 million doses from other developers including Moderna Inc , <a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a>, Johnson &amp; Johnson's and Novavax .</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Samsung BioLogics denies report on Pfizer vaccine production</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSamsung BioLogics denies report on Pfizer vaccine production\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-12 08:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>on Wednesday said a report it was in talks with Pfizer Inc to begin production of the U.S. drugmaker's COVID-19 vaccine in South Korea as early as in August was \"not factual.\"</p>\n<p>The Korea Economic Daily reported earlier that the biotech arm of Samsung Group had been revamping production lines at its plant in Songdo to produce the Pfizer vaccine, which was jointly developed by BioNTech . The plant had the capacity to make up to 1 billion doses per year, the report said, quoting an unnamed high-level government official.</p>\n<p>Samsung BioLogics said in a <a href=\"https://laohu8.com/S/AONE\">one</a>-line filing to the stock exchange that the report was \"not factual\". The company did not respond to requests for more detail.</p>\n<p>Pfizer and the Korea Disease Control and Prevention Agency (KDCA) in charge of COVID-19 vaccine procurement were not immediately available for comment.</p>\n<p>South Korea has a contract with Pfizer to purchase 66 million doses of its COVID-19 vaccine. The country also has contracts to acquire a total of 192 million doses from other developers including Moderna Inc , <a href=\"https://laohu8.com/S/AZNCF\">AstraZeneca Plc</a>, Johnson &amp; Johnson's and Novavax .</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2134269356","content_text":"on Wednesday said a report it was in talks with Pfizer Inc to begin production of the U.S. drugmaker's COVID-19 vaccine in South Korea as early as in August was \"not factual.\"\nThe Korea Economic Daily reported earlier that the biotech arm of Samsung Group had been revamping production lines at its plant in Songdo to produce the Pfizer vaccine, which was jointly developed by BioNTech . The plant had the capacity to make up to 1 billion doses per year, the report said, quoting an unnamed high-level government official.\nSamsung BioLogics said in a one-line filing to the stock exchange that the report was \"not factual\". The company did not respond to requests for more detail.\nPfizer and the Korea Disease Control and Prevention Agency (KDCA) in charge of COVID-19 vaccine procurement were not immediately available for comment.\nSouth Korea has a contract with Pfizer to purchase 66 million doses of its COVID-19 vaccine. The country also has contracts to acquire a total of 192 million doses from other developers including Moderna Inc , AstraZeneca Plc, Johnson & Johnson's and Novavax .","news_type":1},"isVote":1,"tweetType":1,"viewCount":475,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}

Samsung BioLogics denies report on Pfizer vaccine production

评论（3）

热议股票